<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372057</url>
  </required_header>
  <id_info>
    <org_study_id>VS-0145-225</org_study_id>
    <nct_id>NCT03372057</nct_id>
  </id_info>
  <brief_title>A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)</brief_title>
  <official_title>A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual&#xD;
      inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma&#xD;
      (PTCL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has 2 phases, a Dose Optimization Phase and an Expansion Phase.&#xD;
&#xD;
      In the Dose Optimization Phase, patients will be randomly assigned to 1 of 2 study cohorts,&#xD;
      as follows:&#xD;
&#xD;
        -  Cohort 1: Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a&#xD;
           per-patient basis to 50 mg and then 75 mg, based on the patient's response to and&#xD;
           tolerance of therapy, in 28-day cycles.&#xD;
&#xD;
        -  Cohort 2: Duvelisib 75 mg PO BID, administered in 28-day cycles .&#xD;
&#xD;
      A total of 20 patients will be enrolled in the Dose Optimization Phase, with 10 patients per&#xD;
      cohort. Based on the safety and activity data obtained in the Dose Optimization Phase of the&#xD;
      study, the Expansion Phase dose of Duvelisib will be determined.&#xD;
&#xD;
      In the Expansion Phase, approximately 90-100 patients may be enrolled and will receive&#xD;
      Duvelisib dose in 28-day cycles as determined in Dose Optimization Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From start of treatment to first documented response, assessed up to 2 cycles (58 days)</time_frame>
    <description>Best response of CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From start of treatment until disease progression or unacceptable toxicity, assessed up to 2 cycles (58 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v4.0</measure>
    <time_frame>From start of treatment to end of treatment plus 30 days; 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Greater than or equal to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment until death, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who receive the optimal dose of duvelisib</measure>
    <time_frame>From start of treatment to end of cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Optimization Phase: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization Phase: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib 75 mg PO BID, administered in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.</description>
    <arm_group_label>Dose Optimization Phase: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib PO 75 mg BID in 28-day cycles.</description>
    <arm_group_label>Dose Optimization Phase: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)</description>
    <arm_group_label>Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years of age&#xD;
&#xD;
          2. Diagnosis of one of the following histologic subtypes of PTCL,&#xD;
             pathologically-confirmed, as defined by the World Health Organization:&#xD;
&#xD;
               1. Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS);&#xD;
&#xD;
               2. Angioimmunoblastic T-cell lymphomas (AITL);&#xD;
&#xD;
               3. Anaplastic large cell lymphoma (ALCL); or&#xD;
&#xD;
               4. Natural-killer/T-cell lymphoma (NKTL)&#xD;
&#xD;
          3. Received at least 2 cycles of one prior regimen administered with curative intent and&#xD;
             one of the following:&#xD;
&#xD;
               1. failed to achieve at least a partial response after 2 or more cycles;&#xD;
&#xD;
               2. failed to achieve a complete response after 6 or more cycles; and/or&#xD;
&#xD;
               3. progressed after an initial response&#xD;
&#xD;
          4. For patients with CD30+ ALCL, failed or are ineligible or intolerant to brentuximab&#xD;
             vedotin&#xD;
&#xD;
          5. Measurable disease as defined by IWG for PTCL, i.e., at least 1 measurable disease&#xD;
             lesion &gt; 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical evidence of transformation to a more aggressive subtype of lymphoma&#xD;
&#xD;
          2. Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor&#xD;
&#xD;
          3. Known central nervous system involvement by PTCL&#xD;
&#xD;
          4. Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic&#xD;
             steroids &gt; 20 mg of prednisone (or equivalent) once daily (QD)&#xD;
&#xD;
          5. Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cohan, MD</last_name>
    <role>Study Director</role>
    <affiliation>SecuraBio Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danica Katz, MA</last_name>
    <phone>805-390-1311</phone>
    <email>dkatz@securabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Aranki</last_name>
      <email>garanki@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jasmine Zain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Johnson</last_name>
      <email>blakej@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Pinter-Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Catala</last_name>
      <email>MCatala@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Mead, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylan Dixon</last_name>
      <email>kaylan.dixon@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Bearden</last_name>
      <email>jeffrey.bearden1@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Pro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Roberts</last_name>
      <email>joshua.Roberts@nortonhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Woolridge</last_name>
      <email>Heather.Woolridge@nortonhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Maly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Glynn</last_name>
      <email>nglynn@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Seung Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Jeter</last_name>
      <email>Erin_Jeter@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Eric Jacobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen McDaniels, BS</last_name>
      <email>k.mcdaniels@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Neha Mehta-Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Bahgat</last_name>
      <email>bahgata@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Steven Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Lerman</last_name>
      <email>ylerman@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlyn Burrows</last_name>
      <email>Kaitlyn_Burrows@URMC.Rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carla Casulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aisha Hashmi</last_name>
      <email>Aisha.Hashmi@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Huda Salman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Smith</last_name>
      <email>April.Smith@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark LaRocque</last_name>
      <email>mlarocque@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Alan Skarbnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fifi Wolfe</last_name>
      <email>adolfina.wolfe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jie Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univeristy</name>
      <address>
        <city>Columbia</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hema Hema</last_name>
      <email>Hemalatha.rao@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Brammer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Martinez</last_name>
      <email>jmartinez@toledoclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Gadus</last_name>
      <email>tgadus@toledoclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rex Mowat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy O'Connell</last_name>
      <email>oconnellka2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Rafic Farah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute - Charles Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Torrez</last_name>
      <email>Nick.Torrez@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Jana Reynolds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Kleinbauer</last_name>
      <email>antje.kleinbauer@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Böde</last_name>
      <email>ines.boede@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Frank Kroschinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Peruta</last_name>
      <email>bperuta@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.di Bologna Policl.S.Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Zanarini</last_name>
      <email>lisa.zanarini3@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ieo, Irccs</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Menna</last_name>
      <email>simona.menna@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Corrado Tarella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marika Picardi</last_name>
      <email>marika.picardi86@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria di Terni</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviana Appolloni</last_name>
      <email>appolloniviviana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Kaczmarek</last_name>
      <email>rozalia.kaczmarek@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Kim Linton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Sutcliffe</last_name>
      <email>abigail.sutcliffe@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Christopher Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>T-cell Lymphoma</keyword>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <keyword>PI3K-δ,γ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

